Research autopsy programmes in oncology: shared experience from 14 centres across the world
- Author(s)
- Geukens, T; Maetens, M; Hooper, JE; Oesterreich, S; Lee, AV; Miller, L; Atkinson, JM; Rosenzweig, M; Puhalla, S; Thorne, H; Devereux, L; Bowtell, D; Loi, S; Bacon, ER; Ihle, K; Song, M; Rodriguez-Rodriguez, L; Welm, AL; Gauchay, L; Murali, R; Chanda, P; Karacay, A; Naceur-Lombardelli, C; Bridger, H; Swanton, C; Jamal-Hanjani, M; Kollath, L; True, L; Morrissey, C; Chambers, M; Chinnaiyan, AM; Wilson, A; Mehra, R; Reichert, Z; Carey, LA; Perou, CM; Kelly, E; Maeda, D; Goto, A; Kulka, J; Székely, B; Szasz, AM; Tőkés, AM; Van Den Bogaert, W; Floris, G; Desmedt, C;
- Details
- Publication Year 2024-06,Volume 263,Issue #2,Page 150-165
- Journal Title
- Journal of Pathology
- Publication Type
- Research article
- Abstract
- While there is a great clinical need to understand the biology of metastatic cancer in order to treat it more effectively, research is hampered by limited sample availability. Research autopsy programmes can crucially advance the field through synchronous, extensive, and high-volume sample collection. However, it remains an underused strategy in translational research. Via an extensive questionnaire, we collected information on the study design, enrolment strategy, study conduct, sample and data management, and challenges and opportunities of research autopsy programmes in oncology worldwide. Fourteen programmes participated in this study. Eight programmes operated 24 h/7 days, resulting in a lower median postmortem interval (time between death and start of the autopsy, 4 h) compared with those operating during working hours (9 h). Most programmes (n = 10) succeeded in collecting all samples within a median of 12 h after death. A large number of tumour sites were sampled during each autopsy (median 15.5 per patient). The median number of samples collected per patient was 58, including different processing methods for tumour samples but also non-tumour tissues and liquid biopsies. Unique biological insights derived from these samples included metastatic progression, treatment resistance, disease heterogeneity, tumour dormancy, interactions with the tumour micro-environment, and tumour representation in liquid biopsies. Tumour patient-derived xenograft (PDX) or organoid (PDO) models were additionally established, allowing for drug discovery and treatment sensitivity assays. Apart from the opportunities and achievements, we also present the challenges related with postmortem sample collections and strategies to overcome them, based on the shared experience of these 14 programmes. Through this work, we hope to increase the transparency of postmortem tissue donation, to encourage and aid the creation of new programmes, and to foster collaborations on these unique sample collections. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
- Publisher
- Wiley
- Keywords
- Humans; *Autopsy; *Neoplasms/pathology/mortality; *Medical Oncology/methods; Animals; Translational Research, Biomedical; liquid biopsy; metastatic cancer; research autopsy; tissue donation; tumour model
- Department(s)
- Laboratory Research
- Publisher's Version
- https://doi.org/10.1002/path.6271
- Open Access at Publisher's Site
https://doi.org/10.1002/path.6271- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-07-09 04:13:27
Last Modified: 2024-07-09 04:14:11